


Please Direct All Correspondence to Customer Number **20995****AMENDMENT / RESPONSE TRANSMITTAL**

Applicant : Landes, et al.
App. No : 10/726,332
Filed : December 2, 2003
For : ANTIBODIES DIRECTED TO
PHOSPHOLIPASE A2 AND USES
THEREOF
Examiner : Vandervegt, F. P.
Art Unit : 1644

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 13, 2006

(Date)

Mallory K. de Merlier, Reg. No. 51,609

Mail Stop Amendment


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- (X) Response to Amendment and Response to Restriction Requirement in 5 pages.
- (X) Return prepaid postcard.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.


Mallory K. de Merlier
Registration No. 51,609
Attorney of Record
Customer No. 20,995
(619) 235-8550



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Gregory M. Landes, et al.
Appl. No. : 10/726,332
Filed : December 2, 2003
For : ANTIBODIES DIRECTED TO
PHOSPHOLIPASE A2 AND USES
THEREOF
Examiner : Francois P. Vandervegt
Group Art Unit : 1644

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 13, 2006

(Date)

Mallory K. de Merlier, Reg. No. 51,609

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT**Mail Stop Amendment**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement mailed on September 15, 2006, Applicants submit the following amendments and remarks. Applicants hereby elect to prosecute the claims of Group I, Claims 1-16 and 19, drawn to a human monoclonal antibody to phospholipase A2, classified in class 530, subclass 388.15. Additionally, Applicants further elect, SEQ ID NO: 27 and SEQ ID NO: 28, as the specific immunoglobulin heavy chain sequence and light chain sequence, respectively.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 5 of this paper.